Purpura fulminans: recognition, diagnosis and management

Purpura fulminans (PF) is a haematological emergency in which there is skin necrosis and disseminated intravascular coagulation. This may progress rapidly to multi-organ failure caused by thrombotic occlusion of small and medium-sized blood vessels. PF may complicate severe sepsis or may occur as an autoimmune response to otherwise benign childhood infections. PF may also be the presenting symptom of severe heritable deficiency of the natural anticoagulants protein C or protein S. Early recognition and treatment of PF is essential to reduce mortality and to prevent major long-term health sequelae. However, management strategies require accurate identification of the underlying cause. This review focuses on the clinical features, differential diagnosis and laboratory features of the range of PF disorders and includes expert consensus opinion about immediate and on-going management.

[1]  R. Cardigan,et al.  Thrombin generation and clot formation in methylene blue–treated plasma and cryoprecipitate , 2009, Transfusion.

[2]  P. Monagle,et al.  Unfractionated Heparin Therapy in Infants and Children , 2009, Pediatrics.

[3]  A. Mumford,et al.  The protein C ω‐loop substitution Asn2Ile is associated with reduced protein C anticoagulant activity , 2009, British journal of haematology.

[4]  J. Kim,et al.  Long‐term survival of a child with homozygous protein C deficiency successfully treated with living donor liver transplantation , 2009, Pediatric transplantation.

[5]  W. Hop,et al.  Long-term health status in childhood survivors of meningococcal septic shock. , 2008, Archives of pediatrics & adolescent medicine.

[6]  M. Manco‐Johnson,et al.  Protein C deficiency , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  G. Kenet,et al.  Hemostasis and Thrombosis in Critically Ill Children , 2008, Seminars in thrombosis and hemostasis.

[8]  P. Reitsma,et al.  PROS1 analysis in 87 pedigrees with hereditary protein S deficiency demonstrates striking genotype–phenotype associations , 2008, Human mutation.

[9]  P. Knoebl.  Human protein C concentrates for replacement therapy in congenital and acquired protein C deficiency. , 2008, Drugs of today.

[10]  M. Levy,et al.  Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 , 2007, Intensive Care Medicine.

[11]  Mark D. Williams,et al.  Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial , 2007, The Lancet.

[12]  M. Fernández-Burriel.  Severe clinical presentation of protein C deficiency in a type I/II compound heterozygote newborn. , 2005, Thrombosis and haemostasis.

[13]  J. Duguid,et al.  Guidelines for the use of fresh‐frozen plasma, cryoprecipitate and cryosupernatant , 2004, British journal of haematology.

[14]  C. Rodeck,et al.  Transfusion guidelines for neonates and older children , 2004, British journal of haematology.

[15]  K. Khair,et al.  SUBCUTANEOUS ADMINISTRATION OF PROTEIN C CONCENTRATE , 2004, Pediatric hematology and oncology.

[16]  P. Mulder,et al.  Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. , 2003, Critical care medicine.

[17]  T. Iba,et al.  [Disseminated intravascular coagulation]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[18]  R. Sheridan,et al.  Current management of purpura fulminans: a multicenter study. , 2003, The Journal of burn care & rehabilitation.

[19]  B. Childers,et al.  Acute Infectious Purpura Fulminans: A 15-Year Retrospective Review of 28 Consecutive Cases , 2003, The American surgeon.

[20]  E. Chalmers,et al.  The investigation and management of neonatal haemostasis and thrombosis * , 2002, British journal of haematology.

[21]  G. Bernard,et al.  Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis , 2001, Critical care medicine.

[22]  M. Manco‐Johnson,et al.  The Varicella-Autoantibody Syndrome , 2001, Pediatric Research.

[23]  C. Esmon,et al.  Dysfunction of endothelial protein C activation in severe meningococcal sepsis. , 2001, The New England journal of medicine.

[24]  M. Rafferty,et al.  An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. , 2000, Blood.

[25]  M. Hibberd,et al.  Effect of the Factor V Leiden mutation on the severity of meningococcal disease. , 1999, The Pediatric infectious disease journal.

[26]  A. Gurgey.  Clinical manifestations in thrombotic children with factor V Leiden mutation. , 1999, Pediatric hematology and oncology.

[27]  R. Marlar,et al.  Homozygous Protein C Deficiency: Description of a New Mutation and Successful Treatment with Low Molecular Weight Heparin , 1998, Thrombosis and Haemostasis.

[28]  A. Minford,et al.  Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate , 1996, British journal of haematology.

[29]  M. Dreyfus,et al.  Replacement Therapy with a Monoclonal Antibody Purified Protein C Concentrate in Newborns with Severe Congenital Protein C Deficiency , 1995, Seminars in thrombosis and hemostasis.

[30]  M. Aiach,et al.  Identification of mutations in 90 of 121 consecutive symptomatic French patients with a type I protein C deficiency. The French INSERM Network on Molecular Abnormalities Responsible for Protein C and Protein S deficiencies. , 1995, Blood.

[31]  R. Heyderman,et al.  Postinfectious purpura fulminans caused by an autoantibody directed against protein S. , 1995, The Journal of pediatrics.

[32]  A. Minford,et al.  Ophthalmic manifestations of neonatal protein C deficiency. , 1994, The British journal of ophthalmology.

[33]  J. Griffin,et al.  Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency , 1993 .

[34]  R. Marlar,et al.  Severe neonatal protein C deficiency: prevalence and thrombotic risk. , 1991, The Journal of pediatrics.

[35]  M. Hicks,et al.  Dermatopathology of Skin Necrosis Associated with Purpura Fulminans , 1990, Seminars in thrombosis and hemostasis.

[36]  R. Marlar,et al.  Neonatal Purpura Fulminans Due to Homozygous Protein C or Protein S Deficiencies , 1990, Seminars in thrombosis and hemostasis.

[37]  Robert F. Francis,et al.  Acquired Purpura Fulminans , 1990, Seminars in thrombosis and hemostasis.

[38]  J. Paramo,et al.  Types 1 and 2 Plasminogen Activator lnhibitor and Tirmor Necrosis Factor Alpha in Fatients with Sepsis , 1990, Thrombosis and Haemostasis.

[39]  R. Marlar,et al.  Report on the Diagnosis and Treatment of Homozygous Protein C Deficiency , 1989, Thrombosis and Haemostasis.

[40]  W. Hitchcock,et al.  Meningococcal infections in children: a review of 100 cases. , 1989, The Pediatric infectious disease journal.

[41]  R. Marlar,et al.  Diagnosis and treatment of homozygous protein C deficiency , 1989 .

[42]  A. Hoffbrand,et al.  Homozygous protein C deficiency with delayed onset of symptoms at 7 to 10 months. , 1989, Thrombosis research.

[43]  C. Mitchell,et al.  A fatal thrombotic disorder associated with an acquired inhibitor of protein C. , 1987, The New England journal of medicine.

[44]  S. Rapaport,et al.  Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. , 1984, The New England journal of medicine.

[45]  Nandi Ps,et al.  Recognition and management of acute pericarditis. , 1973 .

[46]  C. Chopin,et al.  Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates , 2007, Intensive Care Medicine.

[47]  C. Chopin,et al.  Meningococcemia and purpura fulminans in adults: Acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates , 2005, Intensive Care Medicine.

[48]  W. Piette.  The differential diagnosis of purpura from a morphologic perspective. , 1994, Advances in dermatology.

[49]  J. Griffin,et al.  Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. , 1993, Blood.

[50]  A. McNicholas,et al.  Increased risk of venous thrombosis in carriers of hereditary protein C def iciency defect , 1993 .